Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study

Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study

Background: The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) and dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trials have demonstrated significant kidney benefits with sodium-glucose cotransporter-2...

Full description

Bibliographic Details
Main Authors:	Tae Won Yi, Mohammad Atiquzzaman, Yuyan Zheng, Brendan Smyth, Meg Jardine, Adeera Levin
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-12-01
Series:	Canadian Journal of Kidney Health and Disease
Online Access:	https://doi.org/10.1177/20543581221145068

Similar Items

Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research
by: Tae Won Yi, et al.
Published: (2024-01-01)

Use of Sodium–glucose Cotransporter 2 Inhibitors in Patients with Chronic Kidney Disease
by: Ahmed M Alkhunaizi, et al.
Published: (2023-01-01)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
by: Shingo Kato, et al.
Published: (2022-10-01)

Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor
by: Hyung Ah Jo, et al.
Published: (2023-02-01)

Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease
by: Usama Abdel Azim Sharaf El Din, et al.
Published: (2022-07-01)

Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease
by: Usama Abdel Azim Sharaf El Din, et al.
Published: (2022-07-01)

Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models
by: Giovanna Castoldi, et al.
Published: (2024-03-01)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
by: Anjay Rastogi, et al.
Published: (2023-04-01)

From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
by: Cheng-Yang Hsieh, et al.
Published: (2022-12-01)

A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
by: Shinji Kume, et al.
Published: (2022-05-01)

Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats.
by: Sarika Kapoor, et al.
Published: (2015-01-01)

Sodium-glucose Cotransporter 2 Inhibitors in Kidney Transplant Recipients – A Retrospective Single Center Study
by: Joana Freitas, et al.
Published: (2024-01-01)

Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases
by: Alexander E Berezin, et al.
Published: (2024-02-01)

Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
by: Adrian Post, et al.
Published: (2020-05-01)

Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
by: Xiutian Chen, et al.
Published: (2022-12-01)

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?
by: Aditi Ujjawal, et al.
Published: (2022-04-01)

Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
by: Shin‐ichi Araki
Published: (2020-01-01)

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
by: Daniel Rodriguez, et al.
Published: (2015-12-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019-08-01)

Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
by: Kyung Ae Lee, et al.
Published: (2018-04-01)

Best Practices in the Use of Sodium–Glucose Cotransporter 2 Inhibitors in Diabetes and Chronic Kidney Disease for Primary Care
by: Jay H. Shubrook, et al.
Published: (2023-10-01)

A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review
by: Jinfang Song, et al.
Published: (2023-09-01)

Sodium-Glucose Cotransporter-2 inhibitors utilization and outcomes in patients with chronic kidney disease at a tertiary centre
by: Kuan, Yee L, et al.
Published: (2023)

Prescription Pattern of Cation Exchange Resins and Their Efficacy in Treating Chronic Hyperkalemia Among Patients With Chronic Kidney Diseases: Findings From a Population-Based Analysis in British Columbia, Canada
by: Mohammad Atiquzzaman, et al.
Published: (2022-11-01)

Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage
by: Humberto Reyes-Pardo, et al.
Published: (2019-08-01)

Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
by: Yanling Zhang, et al.
Published: (2016-01-01)

Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
by: Elkeraie AF, et al.
Published: (2024-01-01)

Administration of sodium-glucose cotransporter-2 inhibitors in kidney transplant patients with diabetes: a systematic review and meta-analysis
by: Hamidreza Khodabandeh, et al.
Published: (2023-09-01)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022-02-01)

Impact of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes in patients with chronic kidney disease: propensity score matched analysis
by: Wen Sun, et al.
Published: (2024-01-01)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
by: Sjoukje van der Hoek, et al.
Published: (2023-04-01)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
by: Shen L, et al.
Published: (2021-04-01)

Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria
by: Akinobu Nakamura, et al.
Published: (2020-01-01)

Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease
by: Emma S. Speedtsberg, et al.
Published: (2023-12-01)

Integrated analysis for treatment scheme of sodium–glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study
by: Li Fang, et al.
Published: (2023-04-01)